These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28581126)

  • 21. Cetuximab and the Head and Neck Squamous Cell Cancer.
    Concu R; Cordeiro MNDS
    Curr Top Med Chem; 2018; 18(3):192-198. PubMed ID: 29332581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preoperative chemotherapy for patients with advanced head and neck cancer].
    Tsukuda M
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1806-13. PubMed ID: 11729472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.
    Cancer Biol Ther; 2006 Apr; 5(4):340-2. PubMed ID: 16808060
    [No Abstract]   [Full Text] [Related]  

  • 24. New perspectives in medical approach to therapy of head and neck squamous cell carcinoma.
    Santarelli A; Lo Russo L; Bambini F; Campisi G; Lo Muzio L
    Minerva Stomatol; 2009 Sep; 58(9):445-52. PubMed ID: 19893469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
    Lee YS; Johnson DE; Grandis JR
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):283-299. PubMed ID: 30376740
    [No Abstract]   [Full Text] [Related]  

  • 26. Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
    Burgy M; Barthélémy P; Lefevre F; Dupret-Bories A; Truntzer P; Korenbaum C; Flesch H; Bronner G; Borel C
    Oncology; 2017; 93(1):11-17. PubMed ID: 28423384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
    Papaspyrou G; Werner JA; Dietz A
    Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.
    Devaraja K
    Pharmaceut Med; 2019 Aug; 33(4):269-289. PubMed ID: 31933185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
    Mutlu H; Salim DK; Gündüz Ş; Eryılmaz MK; Musri FY; Coşkun HŞ
    J Cancer Res Ther; 2017; 13(3):510-513. PubMed ID: 28862218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Bourhis J; Lefebvre JL; Vermorken JB
    Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
    Zech HB; Laban S; Schafhausen P; Bussmann L; Betz C; Busch CJ
    HNO; 2019 Dec; 67(12):898-904. PubMed ID: 31701170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations.
    Martinez JC; Otley CC; Okuno SH; Foote RL; Kasperbauer JL
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):679-86. PubMed ID: 15061855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT.
    Colevas AD
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):86-9. PubMed ID: 9348576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects.
    Mozet C; Stoehr M; Dimitrova K; Dietz A; Wichmann G
    Anticancer Res; 2013 Jun; 33(6):2415-24. PubMed ID: 23749890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Immunotherapy in Head and Neck Cancer.
    Ling DC; Bakkenist CJ; Ferris RL; Clump DA
    Semin Radiat Oncol; 2018 Jan; 28(1):12-16. PubMed ID: 29173750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
    Sheth S; Weiss J
    Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Concepts in Chemotherapy for Head and Neck Cancer.
    Sindhu SK; Bauman JE
    Oral Maxillofac Surg Clin North Am; 2019 Feb; 31(1):145-154. PubMed ID: 30449525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
    Haque S; Yellu M; Randhawa J; Hashemi-Sadraei N
    Drug Des Devel Ther; 2017; 11():2537-2549. PubMed ID: 28919706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapy: A novel approach in head and neck cancer.
    Christy AW; Bojan A
    Indian J Dent Res; 2013; 24(2):261-6. PubMed ID: 23965459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab Doubles Survival for Patients with HNSCC.
    Cancer Discov; 2016 Jul; 6(7):OF3. PubMed ID: 27217382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.